Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Regeneron Pharmaceuticals
REGN
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$1150.19
0
0.00%
Pre-Market: 5:02 PM EDT
15 minutes delayed
Get Report
Comment
Regeneron Pharmaceuticals (REGN) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock
Regeneron Pharmaceuticals Stock (NASDAQ: REGN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, September 17, 2024
RBC Capital Reiterates Outperform on Regenero...
Benzinga Newsdesk
Monday, September 16, 2024
Cantor Fitzgerald Reiterates Neutral on Regen...
Benzinga Newsdesk
Friday, September 13, 2024
Regeneron Pharmaceuticals And Sanofi Announce...
Benzinga Newsdesk
Thursday, September 12, 2024
Health Canada Has Issued A Notice Of Complian...
Benzinga Newsdesk
Wednesday, September 11, 2024
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Benzinga Insights
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
Vandana Singh
Regeneron Pharmaceuticals Announced New Analy...
Benzinga Newsdesk
Regeneron And Sanofi's Dupixent (Dupilumab) P...
Benzinga Newsdesk
Regeneron And Sanofi's Dupixent Becomes First...
Benzinga Newsdesk
Tuesday, September 10, 2024
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
Benzinga Insights
Pooled Analysis From Sanofi's BOREAS And NOTU...
Benzinga Newsdesk
Monday, September 09, 2024
Regeneron Reports Five-year Results From Fina...
Benzinga Newsdesk
GSK's Respiratory Drug Nucala Meets Goal in COPD Study
Zacks
Cantor Fitzgerald Reiterates Neutral on Regen...
Benzinga Newsdesk
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
Benzinga Insights
RBC Capital Maintains Outperform on Regeneron...
Benzinga Newsdesk
Thursday, September 05, 2024
RBC Capital Reiterates Outperform on Regenero...
Benzinga Newsdesk
Tuesday, August 27, 2024
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
Zacks
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Benzinga Insights
Monday, August 26, 2024
Regeneron Says European Commission Has Approv...
Benzinga Newsdesk
Regeneron Highlights Scientific Innovation An...
Benzinga Newsdesk
Friday, August 23, 2024
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Benzinga Insights
Piper Sandler Maintains Overweight on Regener...
Benzinga Newsdesk
Wednesday, August 21, 2024
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
Benzinga Neuro
Tuesday, August 20, 2024
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
Benzinga Insights
Tuesday, August 13, 2024
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Benzinga Insights
Thursday, August 08, 2024
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
Benzinga Insights
Friday, August 02, 2024
JP Morgan Maintains Overweight on Regeneron P...
Benzinga Newsdesk
RBC Capital Maintains Outperform on Regeneron...
Benzinga Newsdesk
Guggenheim Maintains Buy on Regeneron Pharmac...
Benzinga Newsdesk
Wells Fargo Maintains Overweight on Regeneron...
Benzinga Newsdesk
Barclays Maintains Overweight on Regeneron Ph...
Benzinga Newsdesk
Analyst Ratings For Regeneron Pharmaceuticals
Benzinga Insights
Truist Securities Reiterates Buy on Regeneron...
Benzinga Newsdesk
Thursday, August 01, 2024
Regeneron Tops on Q2 Earnings, Eylea HD, Dupixent Fuel Sales
Zacks
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Vandana Singh
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Piero Cingari
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Shanthi Rexaline
Regeneron Pharmaceuticals Q2 2024 Adj EPS $11...
Benzinga Newsdesk
Wednesday, July 31, 2024
Should You Invest in the iShares Biotechnology ETF?
Zacks
Tuesday, July 30, 2024
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Benzinga Insights
Monday, July 29, 2024
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Shanthi Rexaline
Thursday, July 25, 2024
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Vandana Singh
Tuesday, July 23, 2024
TD Cowen Maintains Buy on Regeneron Pharmaceu...
Benzinga Newsdesk
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Vandana Singh
Monday, July 22, 2024
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Benzinga Insights
Cantor Fitzgerald Maintains Neutral on Regene...
Benzinga Newsdesk
Friday, July 19, 2024
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Benzinga Insights
Piper Sandler Maintains Overweight on Regener...
Benzinga Newsdesk
Thursday, July 18, 2024
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Vandana Singh
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch